Current Report Filing (8-k)
May 07 2014 - 3:29PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): May 7, 2014
NEKTAR THERAPEUTICS
(Exact Name of Registrant as Specified
in Charter)
Delaware |
0-24006 |
94-3134940 |
(State or Other Jurisdiction |
(Commission |
(IRS Employer |
of Incorporation) |
File Number) |
Identification No.) |
455 Mission Bay Boulevard South
San Francisco, California 94158
(Address of Principal Executive Offices
and Zip Code)
Registrant’s telephone number, including
area code: (415) 482-5300
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 2.02 | Results of Operations
and Financial Condition. |
On May 7, 2014, Nektar Therapeutics, a
Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial
results for the quarter ended March 31, 2014. A copy of the Press Release is furnished herewith as Exhibit 99.1.
On May 1, 2014, Nektar
announced that it would hold a Webcast conference call on May 7, 2014 to review its financial results for the quarter ended March
31, 2014. This conference call is accessible through a link that is posted on the home page and Investor Relations section of
the Nektar website: http://www.nektar.com.
The information in this report, including the exhibit hereto,
is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933,
as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing
with the Securities and Exchange Commission made by Nektar Therapeutics, whether made before or after the date hereof, regardless
of any general incorporation language in such filing.
| Item 9.01 | Financial Statements
and Exhibits. |
Exhibit
No. |
|
Description |
|
|
99.1 |
|
Press release titled “Nektar Therapeutics Reports Financial Results for the First Quarter of 2014” issued by Nektar Therapeutics on May 7, 2014. |
SIGNATURES
Pursuant to the requirement of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
By: |
/s/ Gil M. Labrucherie |
|
|
Gil M. Labrucherie |
|
|
General Counsel and Secretary |
|
|
|
|
Date: |
May 7, 2014 |
EXHIBIT INDEX
Exhibit
No. |
|
Description |
|
|
99.1 |
|
Press release titled “Nektar Therapeutics Reports Financial Results for the First Quarter of 2014” issued by Nektar Therapeutics on May 7, 2014. |
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Apr 2024 to May 2024
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From May 2023 to May 2024